ArticleBMJ open diabetes research & care2024
Should insulin resistance (HOMA-IR), insulin secretion (HOMA-β), and visceral fat area be considered for improving the performance of diabetes risk prediction models.
Article in BMJ open diabetes research & care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The association between triglyceride-glucose index and polycystic ovary syndrome: a systematic review and meta-analysis across different populations.Journal of ovarian research · 2025Pooled it
- Glucose homeostasis and cognitive functions in schizophrenia: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- A systematic review of the association between insulin resistance surrogate indices and bone mineral density.Frontiers in endocrinology · 2024Pooled it
- Altered serum amylin and preptin levels in women with polycystic ovary syndrome: a comparative analysis based on obesity status.Journal of endocrinological investigation · 2026Article
- A Single-Food Substitution Strategy (SFSS) Improves Fat Mass and Metabolic Parameters in MASLD: A Prospective Pilot Study.Nutrients · 2026Article
- Combining glycine with thymoquinone offers a promising strategy for diabetes treatment.Scientific reports · 2026Article
- Semaglutide restores metabolic and structural homeostasis along the gut-heart-metabolic axis in a cafeteria diet-induced obesity model.Scientific reports · 2026Article
- Autotaxin and Lysophosphatidic Acid Circulating Levels Correlate with Body Mass Index in Obese Subjects with MASLD.International journal of molecular sciences · 2026Article
- Triglyceride-glucose index and assisted reproductive outcomes in non-PCOS women: evidence from a propensity score-weighted cohort of 9,903 patients.Journal of ovarian research · 2026Article
- Association between targeted inflammatory proteomics and insulin sensitivity as well as beta-cell function in subjects with normal glucose tolerance.Journal of molecular cell biology · 2026Article
- Porous-starch-encapsulated quercetin remodels the gut microbiota and elevates short-chain fatty acids, alleviating hyperglycaemia-associated phenotypes in T2DM mice.Frontiers in nutrition · 2026Article
- Does Zn-Mediated Regulation of the Kynurenine Pathway Provide the Link Between Periodontal Disease and Diabetes?Biological trace element research · 2026Article
- Association between a clinical pharmacist-led multimodal remote medication intervention and individualized treatment outcomes in patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2026Article
- Leptin/Adiponectin Ratio as a new multidimensional biomarker in obese patients with liver steatosis undergoing VLEKT: results from a pilot study.Frontiers in nutrition · 2026Article
- Effects of a Bioactive Vegetable-Enriched Diet on Autotaxin and Liver Fibrosis in MASLD with Evidence of Sex-Specific Responses: A Pilot Study.Nutrients · 2025Article
- Changes in Apolipoprotein A1-Associated Proteomic Composition After Pioglitazone Treatment Versus Weight Loss.International journal of molecular sciences · 2025Article
- Predictive diagnostic models for newly diagnosed diabetes mellitus in moderate to severe COVID-19: the role of TyG Index, BMI, and inflammatory markers.BMC endocrine disorders · 2025Article
- Article
- Association Between Follistatin and PAI-1 Levels in MASLD Subjects Undergoing a Plant-Based Dietary Intervention.Nutrients · 2025Article
- Application of the C-reactive protein-triglyceride glucose index in predicting the risk of new-onset diabetes in the general population aged 45 years and older: a national prospective cohort study.BMC endocrine disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInsulin resistance and defects in pancreatic beta cells are the two major pathophysiologic abnormalities that underlie type 2 diabetes. In addition, visceral fat area (VFA) is reported to be a stronger predictor for diabetes than body mass index (BMI). Here, we tested whether the performance of diabetes prediction models could be improved by adding HOMA-IR and HOMA-β and replacing BMI with VFA. RESEARCH DESIGN AND
methodsWe developed five prediction models using data from a cohort study (5578 individuals, of whom 94.7% were male, and 943 had incident diabetes). We conducted a baseline model (model 1) including age, sex, BMI, smoking, dyslipidemia, hypertension, and HbA1c. Subsequently, we developed another four models: model 2, predictors in model 1 plus fasting plasma glucose (FPG); model 3, predictors in model 1 plus HOMA-IR and HOMA-β; model 4, predictors in model 1 plus FPG, HOMA-IR, and HOMA-β; model 5, replaced BMI with VFA in model 2. We assessed model discrimination and calibration for the first 10 years of follow-up.
resultsThe addition of FPG to model 1 obviously increased the value of the area under the receiver operating characteristic curve from 0.79 (95% CI 0.78, 0.81) to 0.84 (0.83, 0.85). Compared with model 1, model 2 also significantly improved the risk reclassification and discrimination, with a continuous net reclassification improvement index of 0.61 (0.56, 0.70) and an integrated discrimination improvement index of 0.09 (0.08, 0.10). Adding HOMA-IR and HOMA-β (models 3 and 4) or replacing BMI with VFA (model 5) did not further materially improve the performance.
conclusionsThis cohort study, primarily composed of male workers, suggests that a model with BMI, FPG, and HbA1c effectively identifies those at high diabetes risk. However, adding HOMA-IR, HOMA-β, or replacing BMI with VFA does not significantly improve the model. Further studies are needed to confirm our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.